Literature DB >> 27007006

Brentuximab Vedotin in Combination With Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27007006

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN： 1543-0790


× No keyword cloud information.
  5 in total

Review 1.  Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution.

Authors:  Nancy L Bartlett
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 2.  Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients.

Authors:  Neha Mehta-Shah; Nancy L Bartlett
Journal:  Blood       Date:  2018-03-02       Impact factor: 22.113

Review 3.  CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas.

Authors:  Geetika Bhatt; Kami Maddocks; Beth Christian
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

Review 4.  Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma.

Authors:  Anna Alperovich; Anas Younes
Journal:  Cancer J       Date:  2016 Jan-Feb       Impact factor: 3.360

Review 5.  Brentuximab vedotin: clinical updates and practical guidance.

Authors:  Jun Ho Yi; Seok Jin Kim; Won Seog Kim
Journal:  Blood Res       Date:  2017-12-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.